Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Aims: To assess the effects of body mass index, renal impairment (creatinine clearance), and hepatic impairment (Child‐Pugh Score) on the pharmacokinetics of insulin aspart. Methods: Pharmacokinetics of insulin aspart (injected subcutaneously in the abdomen immediately before a Boost® standardized meal) were characterized in: (1) diabetic subjects with four ranges of BMI values (n = 23); (2) diabetic subjects with varying degrees of renal impairment (normal, n = 6 vs. two ranges of impairment, n = 12); and (3) nondiabetic patients with varying degrees of hepatic impairment (normal, n = 6 vs. three ranges of impairment, n = 18). Results: There was no correlation between any pharmacokinetic variable and the degree of renal or hepatic impairment. Increasing obesity was associated with a decreased apparent clearance per kg body weight (β = −0.0005, SE = 0.0001; P = 0.002), an increased t½ (β = 3.513, SE = 1.636; P = 0.044), and an increased ln(AUC 0−360) and ln(AUC 0−1440) (β = 0.030, SE = 0.013; P = 0.032 and β = 0.039, SE = 0.0132; P = 0.006, respectively). However, obesity‐related changes were smaller than individual variations in parameters. Conclusions: Renal impairment, hepatic impairment, or BMI do not affect the pharmacokinetics of insulin aspart in a clinically significant manner. Abbreviations: AUC 0–1440, area under the plasma concentration curve; BMI, body‐mass index; CL cr, renal clearance of creatinine; CL/F, apparent clearance; CL/F/kg, body weight‐adjusted apparent clearance; Cmax, maximal plasma concentration; FBG, fasting blood glucose; GFR, glomerular filtration rate; HI, human insulin; MRT, mean residence time; PK, pharmacokinetics; t½, half life; tmax, time to maximum concentration; Vz/F, apparent volume of distribution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s5 · Cited by 2,689
Cited by
Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.777428 · Cited by 91
Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
Kiss, I., Arold, G., Roepstorff, C., Bøttcher, S. G., Klim, S., & Haahr, H. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0113-2 · Cited by 75
“However, the pharmacokinetics of other insulin products, including insulin aspart [17, 18] and”
BackgroundMorello, C. (2011) · International Journal of General Medicine · doi:10.2147/ijgm.s26889 · Cited by 71
Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
Kupčová, V., Arold, G., Roepstorff, C., Højbjerre, M., Klim, S., & Haahr, H. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-013-0154-1 · Cited by 40
“Single-dose pharmacokinetic studies involving insulin aspart found that hepatic impairment and renal impairment had no significant impact on insulin aspart pharmacokinetics [17].”
Background
Metadata
- Authors
- Holmes, G., Galitz, L., Hu, P., & Lyness, W.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2005-08
- Volume
- 60
- Issue
- 5
- Pages
- 469-476
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1999246346
- Cited by
- 86
- References
- 1
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. https://app.cochat.ai/papers/10.1111/j.1365-2125.2005.02476.x
- The paper
- Holmes, G., Galitz, L., Hu, P., & Lyness, W. (2005). Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2005.02476.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.